Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | PHGDH | O43175 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27571765 | 0.83 | HCAR2 (0.65) | HCAR2KDM4EMAPT | |
| SCHEMBL13666108 | 0.80 | HCAR2 (1.00) | HCAR2 | |
| SCHEMBL9203345 | 0.80 | HTR1A (0.74) | HCAR2 | |
| SCHEMBL10469604 | 0.79 | HTR1A (0.58) | HCAR2 | |
| SCHEMBL24937833 | 0.78 | HCAR2 (0.56) | HCAR2KDM4EMAPT | |
| SCHEMBL6884485 | 0.77 | KDM4E (0.65) | KDM4EMAPT | |
| SCHEMBL9778394 | 0.76 | PARP1 (0.49) | KDM4EMAPT | |
| Hydrochloric Acid SCHEMBL8401502 | 0.76 | KDM4E (0.68) | KDM4EMAPT | |
| SCHEMBL24937770 | 0.75 | HCAR2 (0.53) | HCAR2KDM4EMAPT | |
| SCHEMBL4558892 | 0.75 | KDM4E (0.71) | KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130156795-A1 | METHODS FOR INHIBITION OF CELL PROLIFERATION, SYNERGISTIC TRANSCRIPTION MODULES AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2013-06-20 | — | — | US | disclosed |
| US-20130156795-A1 | METHODS FOR INHIBITION OF CELL PROLIFERATION, SYNERGISTIC TRANSCRIPTION MODULES AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130156795-A1 | METHODS FOR INHIBITION OF CELL PROLIFERATION, SYNERGISTIC TRANSCRIPTION MODULES AND USES THEREOF | MKI67, DCX, CTCF | HCAR2 4395/4885KDM4E 1314/4885MAPT 4158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.